The pathology of central nervous system inflammatory demyelinating disease accompanying myelin oligodendrocyte glycoprotein autoantibody

[1]  Jörg Schwenk,et al.  DISTINCT , 2022, Proceedings of the 2022 ACM SIGSAC Conference on Computer and Communications Security.

[2]  John J. Chen,et al.  Coexistence of Myelin Oligodendrocyte Glycoprotein and Aquaporin-4 Antibodies in Adult and Pediatric Patients. , 2020, JAMA neurology.

[3]  L. Kremer,et al.  Frequency of myelin oligodendrocyte glycoprotein antibody in multiple sclerosis , 2019, Neurology: Neuroimmunology & Neuroinflammation.

[4]  D. Reich,et al.  Association of Chronic Active Multiple Sclerosis Lesions With Disability In Vivo. , 2019, JAMA neurology.

[5]  D. Arnold,et al.  Serial Anti–Myelin Oligodendrocyte Glycoprotein Antibody Analyses and Outcomes in Children With Demyelinating Syndromes , 2019, JAMA neurology.

[6]  M. Ramanathan,et al.  Epidemiology and treatment of multiple sclerosis in elderly populations , 2019, Nature Reviews Neurology.

[7]  O. Ornatsky,et al.  Multiplexed imaging of immune cells in staged multiple sclerosis lesions by mass cytometry , 2019, bioRxiv.

[8]  J. Mills,et al.  A multicenter comparison of MOG-IgG cell-based assays , 2019, Neurology.

[9]  K. Tyler,et al.  Clinical, Radiologic, and Prognostic Features of Myelitis Associated With Myelin Oligodendrocyte Glycoprotein Autoantibody , 2019, JAMA neurology.

[10]  A. Kermode,et al.  Brain histopathological study and prognosis in MOG antibody‐associated demyelinating pseudotumor , 2019, Annals of clinical and translational neurology.

[11]  M. Reindl,et al.  Myelin oligodendrocyte glycoprotein antibodies in neurological disease , 2018, Nature Reviews Neurology.

[12]  T. Berger,et al.  Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disorders: Toward a New Spectrum of Inflammatory Demyelinating CNS Disorders? , 2018, Front. Immunol..

[13]  B. Weinshenker,et al.  Association of MOG-IgG Serostatus With Relapse After Acute Disseminated Encephalomyelitis and Proposed Diagnostic Criteria for MOG-IgG–Associated Disorders , 2018, JAMA neurology.

[14]  B. Weinshenker,et al.  Myelin Oligodendrocyte Glycoprotein Antibody-Positive Optic Neuritis: Clinical Characteristics, Radiologic Clues, and Outcome. , 2018, American journal of ophthalmology.

[15]  T. Misu,et al.  The pathological features of MOG antibody-positive cerebral cortical encephalitis as a new spectrum associated with MOG antibodies: A case report , 2018, Journal of the Neurological Sciences.

[16]  J. Hainfellner,et al.  Teaching Case 5-2018: Integrated morphological and immunological work-up of neurosurgical specimen allows accurate diagnosis of neuroinflammatory lesions: an example of acute disseminated encephalomyelitis (ADEM) associated with anti-MOG antibodies , 2018, Clinical neuropathology.

[17]  G. Krishnamoorthy,et al.  Pathogenicity of human antibodies against myelin oligodendrocyte glycoprotein , 2018, Annals of neurology.

[18]  H. Lassmann,et al.  The compartmentalized inflammatory response in the multiple sclerosis brain is composed of tissue-resident CD8+ T lymphocytes and B cells , 2018, Brain : a journal of neurology.

[19]  P. Lebranchu,et al.  Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults , 2018, Neurology.

[20]  Jacqueline Palace,et al.  MOG encephalomyelitis: international recommendations on diagnosis and antibody testing , 2018, Journal of Neuroinflammation.

[21]  B. Weinshenker,et al.  Aquaporin-4 and Myelin Oligodendrocyte Glycoprotein Autoantibody Status Predict Outcome of Recurrent Optic Neuritis. , 2018, Ophthalmology.

[22]  F. Paul,et al.  MOG-IgG in primary and secondary chronic progressive multiple sclerosis: a multicenter study of 200 patients and review of the literature , 2018, Journal of Neuroinflammation.

[23]  Jacqueline Palace,et al.  Clinical presentation and prognosis in MOG-antibody disease: a UK study , 2017, Brain : a journal of neurology.

[24]  V. Fung,et al.  Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination , 2017, Journal of Neurology, Neurosurgery, and Psychiatry.

[25]  G. Cantalupo,et al.  Clinical spectrum and IgG subclass analysis of anti-myelin oligodendrocyte glycoprotein antibody-associated syndromes: a multicenter study , 2017, Journal of Neurology.

[26]  K. Rostásy,et al.  Prognostic relevance of MOG antibodies in children with an acquired demyelinating syndrome , 2017, Neurology.

[27]  A. Langerak,et al.  Phenotypic and functional characterization of T cells in white matter lesions of multiple sclerosis patients , 2017, Acta Neuropathologica.

[28]  M. Bradl,et al.  Myelin Oligodendrocyte Glycoprotein: Deciphering a Target in Inflammatory Demyelinating Diseases , 2017, Front. Immunol..

[29]  Chuanzhen Lu,et al.  MOG-antibody associated demyelinating disease of the CNS: A clinical and pathological study in Chinese Han patients , 2017, Journal of Neuroimmunology.

[30]  H. Heinze,et al.  ADEM-like presentation, anti-MOG antibodies, and MS pathology: TWO case reports , 2017, Neurology: Neuroimmunology & Neuroinflammation.

[31]  Jacqueline A Palace,et al.  Distinct brain imaging characteristics of autoantibody-mediated CNS conditions and multiple sclerosis , 2017, Brain : a journal of neurology.

[32]  K. Fujihara,et al.  Bilateral frontal cortex encephalitis and paraparesis in a patient with anti-MOG antibodies , 2017, Journal of Neurology, Neurosurgery, and Psychiatry.

[33]  K. Fujihara,et al.  MOG antibody–positive, benign, unilateral, cerebral cortical encephalitis with epilepsy , 2017, Neurology: Neuroimmunology & Neuroinflammation.

[34]  Siegfried Trattnig,et al.  Slow expansion of multiple sclerosis iron rim lesions: pathology and 7 T magnetic resonance imaging , 2016, Acta Neuropathologica.

[35]  F. Paul,et al.  MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: Frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin , 2016, Journal of Neuroinflammation.

[36]  A. Ghezzi,et al.  Pediatric multiple sclerosis , 2016, Neurology.

[37]  C. Mummery,et al.  Inflammatory demyelination without astrocyte loss in MOG antibody–positive NMOSD , 2016, Neurology.

[38]  Michael Haberl,et al.  Autoantibody-boosted T-cell reactivation in the target organ triggers manifestation of autoimmune CNS disease , 2016, Proceedings of the National Academy of Sciences.

[39]  F. Paul,et al.  Screening for MOG-IgG and 27 other anti-glial and anti-neuronal autoantibodies in ‘pattern II multiple sclerosis’ and brain biopsy findings in a MOG-IgG-positive case , 2016, Multiple sclerosis.

[40]  C. Tan.  International consensus diagnostic criteria for neuromyelitis optica spectrum disorders , 2016, Neurology.

[41]  K. Fujihara,et al.  Fulminant demyelinating encephalomyelitis , 2015, Neurology: Neuroimmunology & Neuroinflammation.

[42]  Istvan Pirko,et al.  Clinical and pathological insights into the dynamic nature of the white matter multiple sclerosis plaque , 2015, Annals of neurology.

[43]  A. Traboulsee,et al.  International consensus diagnostic criteria for neuromyelitis optica spectrum disorders , 2015, Neurology.

[44]  J. Benito-León,et al.  Antibodies to MOG and AQP4 in adults with neuromyelitis optica and suspected limited forms of the disease , 2015, Multiple sclerosis.

[45]  K. Fujihara,et al.  Severe demyelination but no astrocytopathy in clinically definite neuromyelitis optica with anti-myelin-oligodendrocyte glycoprotein antibody , 2015, Multiple sclerosis.

[46]  A. Straube,et al.  Histopathology and clinical course of MOG-antibody-associated encephalomyelitis , 2015, Annals of clinical and translational neurology.

[47]  J. Parisi,et al.  Diagnostic utility of aquaporin-4 in the analysis of active demyelinating lesions , 2015, Neurology.

[48]  D. Booth,et al.  Antibodies to MOG have a demyelination phenotype and affect oligodendrocyte cytoskeleton , 2014, Neurology: Neuroimmunology & Neuroinflammation.

[49]  M. Papadopoulos,et al.  Neuromyelitis optica MOG-IgG causes reversible lesions in mouse brain , 2014, Acta neuropathologica communications.

[50]  Simon Hametner,et al.  Disease-specific molecular events in cortical multiple sclerosis lesions , 2013, Brain : a journal of neurology.

[51]  G. Giovannoni,et al.  Cerebrospinal fluid oligoclonal bands in multiple sclerosis and clinically isolated syndromes: a meta-analysis of prevalence, prognosis and effect of latitude , 2013, Journal of Neurology, Neurosurgery & Psychiatry.

[52]  B. Weinshenker,et al.  Effects of age and sex on aquaporin-4 autoimmunity. , 2012, Archives of neurology.

[53]  A. Lutterotti,et al.  Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders , 2011, Journal of Neuroinflammation.

[54]  B. Scheithauer,et al.  Inflammatory cortical demyelination in early multiple sclerosis. , 2011, The New England journal of medicine.

[55]  J. Parisi,et al.  Absence of cortical demyelination in neuromyelitis optica , 2010, Neurology.

[56]  B. Scheithauer,et al.  Perivenous demyelination: association with clinically defined acute disseminated encephalomyelitis and comparison with pathologically confirmed multiple sclerosis. , 2010, Brain : a journal of neurology.

[57]  Hans Lassmann,et al.  The relation between inflammation and neurodegeneration in multiple sclerosis brains , 2009, Brain : a journal of neurology.

[58]  H. Savolainen.  CORTICAL DEMYELINATION IN PML AND MS: SIMILARITIES AND DIFFERENCES , 2009, Neurology.

[59]  R. Huber,et al.  Demyelinating Myelin Oligodendrocyte Glycoprotein-Specific Autoantibody Response Is Focused on One Dominant Conformational Epitope Region in Rodents12 , 2008, The Journal of Immunology.

[60]  B. Weinshenker,et al.  Acute Disseminated Encephalomyelitis: Current Understanding and Controversies , 2008, Seminars in neurology.

[61]  F. Eichler,et al.  Cortical demyelination in PML and MS , 2008, Neurology.

[62]  A. Bar-Or,et al.  Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein , 2007, Nature Medicine.

[63]  F. Fazekas,et al.  Notch1 and its ligand Jagged1 are present in remyelination in a T-cell- and antibody-mediated model of inflammatory demyelination , 2007, Acta Neuropathologica.

[64]  H. Lassmann,et al.  Cortical Demyelination Can Be Modeled in Specific Rat Models of Autoimmune Encephalomyelitis and Is Major Histocompatability Complex (MHC) Haplotype-Related , 2006, Journal of neuropathology and experimental neurology.

[65]  A. Verkman,et al.  The Journal of Experimental Medicine CORRESPONDENCE , 2005 .

[66]  Hans Lassmann,et al.  Multiple Sclerosis Pathology: Evolution of Pathogenetic Concepts , 2005, Brain pathology.

[67]  H. Ulmer,et al.  Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event. , 2003, The New England journal of medicine.

[68]  K. Jellinger,et al.  Preferential Loss of Myelin‐Associated Glycoprotein Reflects Hypoxia‐Like White Matter Damage in Stroke and Inflammatory Brain Diseases , 2003, Journal of neuropathology and experimental neurology.

[69]  J. Parisi,et al.  Heterogeneity of multiple sclerosis lesions: Implications for the pathogenesis of demyelination , 2000, Annals of neurology.

[70]  T. Johns,et al.  The Structure and Function of Myelin Oligodendrocyte Glycoprotein , 1999, Journal of neurochemistry.

[71]  H. Lassmann,et al.  Autoimmunity to Myelin Oligodendrocyte Glycoprotein in Rats Mimics the Spectrum of Multiple Sclerosis Pathology , 1998, Brain pathology.

[72]  H. Lassmann,et al.  MHC haplotype-dependent regulation of MOG-induced EAE in rats. , 1998, The Journal of clinical investigation.

[73]  Hans Lassmann,et al.  Monocyte/macrophage differentiation in early multiple sclerosis lesions , 1995, Annals of neurology.

[74]  J. Matthieu,et al.  Antibodies to Myelin/Oligodendrocyte‐Specific Protein and Myelin/Oligodendrocyte Glycoprotein Signal Distinct Changes in the Organization of Cultured Oligodendroglial Membrane Sheets , 1994, Journal of neurochemistry.

[75]  H. Lassmann,et al.  Interferon‐γ potentiates antibody‐mediated demyelination in vivo , 1992 .

[76]  H. Lassmann,et al.  The demyelinating potential of antibodies to myelin oligodendrocyte glycoprotein is related to their ability to fix complement , 1991, Journal of Neuroimmunology.

[77]  H. Lassmann,et al.  Antibody‐mediated demyelination in experimental allergic encephalomyelitis is independent of complement membrane attack complex formation , 1991, Clinical and experimental immunology.

[78]  H. Lassmann,et al.  Differential Ultrastructural Localization of Myelin Basic Protein, Myelin/Oligodendroglial Glycoprotein, and 2′,3′‐Cyclic Nucleotide 3′‐Phosphodiesterase in the CNS of Adult Rats , 1989, Journal of neurochemistry.

[79]  H. Lassmann,et al.  Augmentation of demyelination in rat acute allergic encephalomyelitis by circulating mouse monoclonal antibodies directed against a myelin/oligodendrocyte glycoprotein. , 1988, The American journal of pathology.

[80]  H. Lassmann,et al.  Antibody responses in chronic relapsing experimental allergic encephalomyelitis: correlation of serum demyelinating activity with antibody titre to the myelin/oligodendrocyte glycoprotein (MOG) , 1987, Journal of Neuroimmunology.

[81]  J. Kurtzke.  Rating neurologic impairment in multiple sclerosis , 1983, Neurology.

[82]  S. Ludwin,et al.  Evidence for a “dying‐back” gliopathy in demyelinating disease , 1981, Annals of neurology.

[83]  M. Duddy,et al.  Seizures and Encephalitis in Myelin Oligodendrocyte Glycoprotein IgG Disease vs Aquaporin 4 IgG Disease , 2018, JAMA neurology.

[84]  Hans Lassmann,et al.  An updated histological classification system for multiple sclerosis lesions , 2016, Acta Neuropathologica.

[85]  H. Lassmann,et al.  Experimental allergic encephalomyelitis: the balance between encephalitogenic T lymphocytes and demyelinating antibodies determines size and structure of demyelinated lesions , 2004, Acta Neuropathologica.

[86]  H. Lassmann,et al.  Interferon-gamma potentiates antibody-mediated demyelination in vivo. , 1992, Annals of neurology.